ELANE and neoplasm: Therapeutic strategies aimed at modulating N1/N2 balance are advancing, with CXCR2 inhibitors, TGF-β pathway blockade, neutrophil elastase inhibition, and immune checkpoint combinations demonstrating meaningful reductions in N2 infiltration and enhanced tumor control in preclinical models.